How should ifosfamide, doxorubicin, and mesna be administered in a chemotherapy regimen?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Administration of Ifosfamide, Doxorubicin, and Mesna

Mesna must be administered concurrently with ifosfamide to prevent hemorrhagic cystitis, using either an all-intravenous regimen (60% total daily mesna dose) or a combined IV/oral regimen (100% total daily mesna dose), while doxorubicin is given as a separate infusion on day 1 of each cycle. 1

Mesna Administration Protocols

All-Intravenous Regimen (Standard-Dose Ifosfamide <2.5 g/m²/day)

For short infusion ifosfamide, administer mesna as three bolus IV injections totaling 60% of the ifosfamide dose: 2, 1

  • 20% of ifosfamide dose given 15 minutes before ifosfamide administration
  • 20% of ifosfamide dose given 4 hours after ifosfamide
  • 20% of ifosfamide dose given 8 hours after ifosfamide

Example: For ifosfamide 1.2 g/m², give mesna 240 mg/m² at 0 hours, 240 mg/m² at 4 hours, and 240 mg/m² at 8 hours 1

Combined IV/Oral Regimen (For Ifosfamide ≤2.0 g/m²/day)

This FDA-approved alternative provides equivalent urothelial protection with improved convenience: 2, 1

  • 20% of ifosfamide dose IV at time of ifosfamide administration
  • 40% of ifosfamide dose orally at 2 hours after ifosfamide
  • 40% of ifosfamide dose orally at 6 hours after ifosfamide
  • Total daily mesna dose = 100% of ifosfamide dose

Critical caveat: If vomiting occurs within 2 hours of oral mesna, repeat the oral dose or switch to IV mesna 2, 1

Continuous Infusion Ifosfamide Protocol

For continuous-infusion ifosfamide, use this modified approach: 2

  • 20% bolus of total ifosfamide dose before starting infusion
  • 40% continuous infusion of ifosfamide dose, continuing for 12-24 hours after ifosfamide completion

Doxorubicin Administration

Standard Combination Regimens

In combination protocols with ifosfamide, doxorubicin dosing varies by regimen: 3, 4, 5, 6

  • AIM regimen: Doxorubicin 60 mg/m² IV over 2 hours on day 1, with ifosfamide 2500 mg/m² on days 1-3 3
  • Modified MAID: Doxorubicin 20 mg/m² over 0.5 hours on days 1-3, with ifosfamide 2500 mg/m² on days 1-3 4
  • ECOG protocol: Doxorubicin 30 mg/m² on days 1-2, with ifosfamide 3750 mg/m² on days 1-2 5

Cycles are repeated every 21 days across all regimens 3, 4, 5

Practical Administration Details

Preparation and Compatibility

Mesna dilution: Dilute to final concentration of 20 mg/mL in 5% dextrose, normal saline, or lactated Ringer's solution 1

Critical incompatibility warning: Do not mix mesna with epirubicin, cyclophosphamide, cisplatin, carboplatin, or nitrogen mustard 1

Ifosfamide-mesna mixing: May be mixed in same bag only if final ifosfamide concentration does not exceed 50 mg/mL (benzyl alcohol in mesna vials reduces ifosfamide stability at higher concentrations) 1

Stability and Storage

  • Diluted mesna solutions: Use within 24 hours when stored at 25°C (77°F) 1
  • Multidose vials: May be used up to 8 days after initial puncture 1

Monitoring Requirements

Essential Surveillance

Maintain adequate hydration and monitor urine for hematuria throughout treatment 1

If severe hematuria develops despite appropriate mesna dosing, consider ifosfamide dose reduction or discontinuation 1

Hematologic monitoring is critical, as myelosuppression is the predominant toxicity with grade 3-4 neutropenia occurring in 47-88% of patients 3, 4, 5, 7

High-Dose Ifosfamide Considerations

For very high-dose ifosfamide (>2.5 g/m²/day), the optimal mesna dosing has not been established 2

Given the longer half-life at these doses, more frequent and prolonged mesna regimens may be necessary for maximum urotoxicity protection 2

The IV/oral regimen efficacy has not been established for daily ifosfamide doses higher than 2 g/m² 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.